Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma
Authors
Keywords
-
Journal
NEURO-ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2018-04-05
DOI
10.1093/neuonc/noy054
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy
- (2017) Timothy F Cloughesy et al. NEURO-ONCOLOGY
- Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab—a report from the BELOB trial
- (2017) Renske Gahrmann et al. NEURO-ONCOLOGY
- Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy
- (2017) Patrick Y Wen et al. NEURO-ONCOLOGY
- Lomustine and Bevacizumab in Progressive Glioblastoma
- (2017) Wolfgang Wick et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Review of VEGF/VEGFR-Targeted Therapeutics for Recurrent Glioblastoma
- (2017) David A. Reardon et al. Journal of the National Comprehensive Cancer Network
- Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials
- (2016) Benjamin M. Ellingson et al. NEURO-ONCOLOGY
- Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo
- (2016) Julia Onken et al. Oncotarget
- Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma
- (2015) L Zhou et al. ONCOGENE
- Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial
- (2014) Walter Taal et al. LANCET ONCOLOGY
- Gene Expression Profile Identifies Tyrosine Kinase c-Met as a Targetable Mediator of Antiangiogenic Therapy Resistance
- (2013) A. Jahangiri et al. CLINICAL CANCER RESEARCH
- Cabozantinib in Progressive Medullary Thyroid Cancer
- (2013) Rossella Elisei et al. JOURNAL OF CLINICAL ONCOLOGY
- CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010
- (2013) Q. T. Ostrom et al. NEURO-ONCOLOGY
- Effects of Dual Targeting of Tumor Cells and Stroma in Human Glioblastoma Xenografts with a Tyrosine Kinase Inhibitor against c-MET and VEGFR2
- (2013) Anna C. Navis et al. PLoS One
- Recurrent Glioblastoma Treated with Bevacizumab: Contrast-enhanced T1-weighted Subtraction Maps Improve Tumor Delineation and Aid Prediction of Survival in a Multicenter Clinical Trial
- (2013) Benjamin M. Ellingson et al. RADIOLOGY
- VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex
- (2012) Kan V. Lu et al. CANCER CELL
- Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial
- (2012) David C. Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer
- (2011) W.-K. You et al. CANCER RESEARCH
- Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
- (2011) Razelle Kurzrock et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
- (2011) F. M. Yakes et al. MOLECULAR CANCER THERAPEUTICS
- Bevacizumab and Irinotecan in the Treatment of Recurrent Malignant Gliomas
- (2010) John F. de Groot et al. CANCER JOURNAL
- Inhibition of Mer and Axl Receptor Tyrosine Kinases in Astrocytoma Cells Leads to Increased Apoptosis and Improved Chemosensitivity
- (2010) A. K. Keating et al. MOLECULAR CANCER THERAPEUTICS
- An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies
- (2010) X Ye et al. ONCOGENE
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
- (2009) Henry S. Friedman et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
- (2009) Roger Stupp et al. LANCET ONCOLOGY
- Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival
- (2009) C. Gjerdrum et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors
- (2008) Felix Bokstein et al. CANCER
- Prognostic significance of c-Met expression in glioblastomas
- (2008) Doo-Sik Kong et al. CANCER
- Axl and Growth Arrest Specific Gene 6 Are Frequently Overexpressed in Human Gliomas and Predict Poor Prognosis in Patients with Glioblastoma Multiforme
- (2008) M. Hutterer et al. CLINICAL CANCER RESEARCH
- Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
- (2008) Teri N. Kreisl et al. JOURNAL OF CLINICAL ONCOLOGY
- Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety
- (2008) Tyler Y. Kang et al. JOURNAL OF NEURO-ONCOLOGY
- Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence
- (2008) A. D. Norden et al. NEUROLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started